The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis Source: Eur Respir Monogr 2020; 88: 279-286 Year: 2020
Rho kinase inhibitors for pulmonary hypertension: waiting for clinical evidence Source: Eur Respir J 2010; 36: 709-711 Year: 2010
JAK inhibitors overcome corticosteroid insensitivity in COPD Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Community acquired pneumonia: an increased risk for subsequent cardiovascular events? Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020
TB failures, risk factors and therapeutical results Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance–pharmacodynamic study Source: Eur Respir J, 53 (5) 1802472; 10.1183/13993003.02472-2018 Year: 2019
Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020
Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation Source: Eur Respir J 2011; 38: 749-751 Year: 2011
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
Pulmonary complications of tyrosine kinase inhibitors in myeloproliferative disorders Source: Eur Respir J, 56 (4) 2002653; 10.1183/13993003.02653-2020 Year: 2020
Known and emerging risk factors for asthma development: is prevention possible? Source: International Congress 2015 – Asthma: emerging risk factors and current management of the patient Year: 2015
PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Prolonged anticoagulation in VTE with direct oral anticoagulants: towards an individual analysis of net clinical benefit? Source: Eur Respir J 2016; 48: 1268-1270 Year: 2016
Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension Source: Eur Respir J , 49 (2) 1602522; DOI: 10.1183/13993003.02522-2016 Year: 2017
The frequency of chronic thromboembolic pulmonary hypertension and associated risk factors Source: Annual Congress 2011 - Prediction of pulmonary thromboembolism Year: 2011
Management of acute pulmonary thrombo-embolic disease (PTE) linking mortality risk to treatment strategies Source: Annual Congress 2009 - Pulmonary circulation II Year: 2009
The selective Rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates experimental pulmonary hypertension Source: International Congress 2017 – Experimental PH Year: 2017
Incidence and specific risk factors of falling in pulmonary rehabilitation Source: Annual Congress 2010 - Pulmonary rehabilitation: understanding and developing the intervention Year: 2010
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities Source: Eur Respir J 2014; 44: 513-522 Year: 2014
An innovative risk score for prediction of asthma related adverse outcome Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009